Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Publisher



Alavian SM1 ; Nikfar S2 ; Kebriaeezadeh A2 ; Lotfi F3 ; Sanati E2 ; Hemami MR4 ; Keshavarz K3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran
  2. 2. Department of Pharmaco economics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Health Human Resource Research Center, School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
  4. 4. Institute of Health and Wellbeing, Health Economics and Health Technology Assessment, University of Glasgow, United Kingdom

Source: Iranian Red Crescent Medical Journal Published:2016


Abstract

Background: Despite the introduction of new drug regimens with high effectiveness for the hepatitis C virus (HCV) patients, especially in HCV genotype 1, no cost-effectiveness study on the selection of the superior drug strategy in Iran has been conducted yet. Objectives: This study is aimed to assess the cost-effectiveness of the three drug regimens of pegylated interferon and ribavirin (PR), sofosbuvir (SOF) + PR and ledipasvir and sofosbuvir (LDV/SOF) in patients with HCV genotype 1 in Iran in the year 2014. Methods: A Markov micro-simulation model was used to evaluate the cost-effectiveness of the three drug strategies for a cohort of 10000 patients. Quality-adjusted life-years (QALYs) were extracted from published studies. Cost data was estimated through the review of medical records and obtaining experts opinion. Results: The results showed that the SOF + PR drug compared with PR had a lower cost and was more effective, but compared with the LDV/SOF, in spite of its lower cost, it was less efficient. The QALY values obtained for PR, SOF + PR and LDV/SOF, respectively, were 10.98, 12.08 and 12.28 and their costs were $ 41,741, $ 7,676 and $ 46,993. Moreover, the results obtained from acceptability curves showed that SOF + PR were the most cost-effective treatment for thresholds below $ 45,270 PPP. Conclusions: The use of SOF + PR regimen or LDV/SOF can significantly reduce the incidence of complications associated with the disease. For example, short and long-term outcomes are better than the current drug regimens for HCV genotype 1 patients in all stages of the disease. © 2016, Iranian Red Crescent Medical Journal.
Related Docs
1. A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With Hbeag-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model, Hepatitis Monthly (2016)
2. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline, Hepatitis Monthly (2016)
3. The Present and Future Disease Burden of Hepatitis C Virus Infections With Today's Treatment Paradigm - Volume 3, Journal of Viral Hepatitis (2015)
4. Cost-Effectiveness of Alemtuzumab and Natalizumab for Relapsing-Remitting Multiple Sclerosis Treatment in Iran: Decision Analysis Based on an Indirect Comparison, Journal of Medical Economics (2019)
5. Naturally Occurring Ns5a and Ns5b Resistant Associated Substitutions in Hcv and Hcv/Hiv Patients in Iranian Population, Clinics and Research in Hepatology and Gastroenterology (2019)
6. Changes in Liver Fibrosis in Patients With Chronic Hepatitis C After Successful Direct-Acting Antiviral Therapy, International Journal of Clinical Practice (2021)
Experts (# of related papers)
View all Related Experts
Reza Malekzadeh (2)
Shekoufeh Nikfar (1)